DUSP6/MKP-3: a phosphatase which helps in the interaction of MEK/ERK signal pathway and PI3K/mTOR

被引：0
|
作者：
Bermudez, O. [1 ]
Marchetti, S. [2 ]
Pages, G. [1 ]
Gimond, C. [1 ]
机构：
[1] Ctr Antoine Lacassagne, CNRS, Inst Canc & Dev Biol, UMR 6543, F-06054 Nice, France
[2] Fac Med, INSERM, U526, Nice, France
来源：
BULLETIN DU CANCER | 2008年 / 95卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
39
引用
收藏
页码：596 / 596
页数：1
相关论文
共 50 条
  • [41] Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
    S Zhou
    L Liu
    H Li
    G Eilers
    Y Kuang
    S Shi
    Z Yan
    X Li
    J M Corson
    F Meng
    H Zhou
    Q Sheng
    J A Fletcher
    W-B Ou
    British Journal of Cancer, 2014, 110 : 2479 - 2488
  • [42] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
  • [43] Targeting the PI3K/mTOR pathway hematologic malignancies
    Tasian, Sarah K.
    Teachey, David T.
    Rheingold, Susan R.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [44] THE PI3K/AKT MTOR PATHWAY IN OLIGODENDROCYTE DIFFERENTIATION
    Wood, T.
    Tyler, W.
    Gangoli, N.
    Gokina, P.
    Kim, H.
    Covey, M.
    Levison, S.
    GLIA, 2009, 57 (13) : S20 - S20
  • [45] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [46] Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development
    Li, Chaoying
    Scott, Daryl A.
    Hatch, Ekaterina
    Tian, Xiaoyan
    Mansour, Suzanne L.
    DEVELOPMENT, 2007, 134 (01): : 167 - 176
  • [47] Hijacking the PI3K/mTor and KRas/MEK/ERK signaling pathways with a therapeutic assault results in robust antitumor activity in PI3K/KRas and KRas mutant tumors
    Vincent, Loic
    Thomas, Anne
    Ma, Jianguo
    Clark, Anderson
    Shaw, Jamie
    Guerif, Stephane
    Egile, Coumaran
    Lager, Joanne
    Debussche, Laurent
    Lengauer, Christoph
    Garcia-Echeverria, Carlos
    Ogden, Janet A.
    CANCER RESEARCH, 2011, 71
  • [48] Effect of everolimus and gefitinib on PI3K/akt/mTOR and raf/MEK/ERK pathways in NSCLC cells.
    Dong, S.
    Zhang, X.
    Chang, H.
    Guo, A.
    Zhu, J.
    Yang, S.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
    Dworakowska, D.
    Wlodek, E.
    Leontiou, C. A.
    Igreja, S.
    Cakir, M.
    Teng, M.
    Prodromou, N.
    Goth, M. I.
    Grozinsky-Glasberg, S.
    Gueorguiev, M.
    Kola, B.
    Korbonits, M.
    Grossman, A. B.
    ENDOCRINE-RELATED CANCER, 2009, 16 (04) : 1329 - 1338
  • [50] m6A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer
    Zhao, Qijie
    Zhao, Yueshui
    Hu, Wei
    Zhang, Yan
    Wu, Xu
    Lu, Jianwei
    Li, Mingxing
    Li, Wei
    Wu, Weiqing
    Wang, Jianhong
    Du, Fukuan
    Ji, Huijiao
    Yang, Xiao
    Xu, Zhenyu
    Wan, Lin
    Wen, Qinglian
    Li, Xiang
    Cho, Chi Hin
    Zou, Chang
    Shen, Jing
    Xiao, Zhangang
    THERANOSTICS, 2020, 10 (21): : 9528 - 9543
12345